Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-06
2007-03-06
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C514S374000, C514S422000, C514S423000, C546S279100, C548S200000, C548S236000, C548S527000, C548S537000
Reexamination Certificate
active
10636001
ABSTRACT:
The present invention relates to acylated arylcycloalkylamines, to pharmaceutical compositions comprising such compounds, to methods for the stimulation of the expression of endothelial NO synthase, and methods of treatment comprising administering such compounds.
REFERENCES:
patent: 3192229 (1965-06-01), Biel
patent: 4614810 (1986-09-01), Georglev et al.
patent: 5849766 (1998-12-01), Jakubowski et al.
patent: 5945431 (1999-08-01), Jin et al.
patent: 6008240 (1999-12-01), Phillips et al.
patent: 6617359 (2003-09-01), Wohlfart et al.
patent: 6759412 (2004-07-01), Strobel
patent: 6812253 (2004-11-01), Wohlfart et al.
patent: 6949556 (2005-09-01), Strobel
patent: 2003/0055093 (2003-03-01), Strobel
patent: 2004/0092513 (2004-05-01), Strobel
patent: 2004/0110808 (2004-06-01), Strobel
patent: 2004/0225013 (2004-11-01), Strobel
patent: 2005/0049237 (2005-03-01), Atkinson et al.
patent: 2005/0054729 (2005-03-01), Strobel
patent: 2005/0101599 (2005-05-01), Zeiher
patent: 0237028 (1987-09-01), None
patent: WO98/36749 (1998-08-01), None
patent: WO99/47153 (1999-09-01), None
patent: WO00/03746 (2000-01-01), None
patent: WO02/20530 (2002-03-01), None
patent: WO 02/064146 (2002-08-01), None
patent: WO 02/064545 (2002-08-01), None
patent: WO 02/064546 (2002-08-01), None
patent: WO 02/064565 (2002-08-01), None
patent: WO 2003037274 (2003-05-01), None
Chang, et al. “Substituted Imidazoles and Glucagon Receptor Antagonists,” Bioorg. and Med. Chem. Letts., (2001) pp. 2549-2553.
Mateos-Careres et al. “Prior Asprin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutorphils” European J. of Clinical Investigation (20020) 32, 895-900.
Freedman et al. “Nitric Oxide and its relationship to thrombotic disorders” J. Thrombosis and Haemostasis, 1: 1183-1188 (2003).
Mateos-Careres et al. European J. of Clinical Investigation (2002) 32, 895-900.
Freedman et al. J. Thrombosis and Haemostasis, 1:1183-1188 (2003).
Aggarwal, et al., Catalytic Cyclopropanation Of Alkenes Using Diazo Compounds Generated In Situ. A Novel Route To 2-Arylcyclopropylamines, Org. Letters, 2001, 3 (17) 2785-2788.
Brown, et al., Organoboranes For Synthesis 7. An Improved General Synthesis of Primary Amines From Alkenes via Hydroboration-Organoborane Chemistry, Terahedron, 1987, 43 (18), 4071-4078.
Coutts, et al., Neurochemical and Neuropharmacological Properties of 4-Fluorotranylcypromine, Cell. Mol. Neurobiol., 1987, 7 (3), 271-291.
Endres, et al., Stroke Protection By 3-hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors Mediated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 1998, 95, 8880-8885.
Li, et al., Activation Of Protein Kinase Ca and or e Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol., 1998, 53, 630-637.
Moroi, et al., Interaction Of Genetic Deficiency Of Endothelial Nitric Oxide, Gender, and Pregnancy In Vascular Response To Injury In Mice, J. Clin. Invest., 1998, 101 (6), 1225-1232.
Nakayama, et al. , T-786- C Mutation in the 5′ -Flanking Region Of The Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Circulation, 1999, 99, 2864-2870.
Sessa, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research, 1994, 74, 349-353.
Varenne, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 2000, 11, 1329-1339.
Wiehl, et al. , Synthese Und Absolute Konfiguration 2-Substituierter Cyclopentanamine, Chem. Ber. 1986, 119, 2668-2677.
Below Peter
Strobel Hartmut
Wohlfart Paulus
Grazier Nyeemah
Knight Julie Anne
Lin Jiang
Saeed Kamal A.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Acylated arylcycloalkylamines and their use as pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated arylcycloalkylamines and their use as pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated arylcycloalkylamines and their use as pharmaceuticals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3790512